Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischaemic stroke
| ISRCTN | ISRCTN71371114 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN71371114 |
| Protocol serial number | N/A |
| Sponsor | National Science Council (Taiwan) |
| Funder | National Science Council (Taiwan) (ref: NSC-97-2314-B-182A-090-MY2) |
- Submission date
- 23/11/2010
- Registration date
- 10/01/2011
- Last edited
- 14/01/2016
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Circulatory System
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Hon-Kan Yip
Scientific
Scientific
123, Ta Pei Road
Niao Sung Hsiang
Kaohsiung Hsien
83301
Taiwan
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Prospective randomised placebo-controlled trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischaemic stroke: a prospective randomised placebo controlled trial |
| Study objectives | Erythropoietin (EPO) enhances circulating level of endothelial progenitor cells (EPCs) which has been reported to be associated with prognostic outcome in ischaemic stroke (IS) patients. This study aimed at evaluating the time course of circulating EPC level and the impact of EPO therapy on EPC level and clinical outcome in patients after acute IS. |
| Ethics approval(s) | Chang Gung Memorial Hospital Research Ethics Committee, 30/01/2008, ref: 96-1381A |
| Health condition(s) or problem(s) studied | Acute ischaemic stroke |
| Intervention | Two consecutive doses of EPO (5,000 IU each time, subcutaneously) administered at 48 hours and 72 hours after acute IS. |
| Intervention type | Other |
| Primary outcome measure(s) |
90-day combined major adverse neurological event (MANE) defined as: |
| Key secondary outcome measure(s) |
To establish the time course of circulating level of EPCs in patients after acute IS and the ability of two doses of EPO in enhancing circulating EPC level |
| Completion date | 31/12/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 220 |
| Key inclusion criteria | Patients aged greater than 45 years, either sex |
| Key exclusion criteria | Patients with history of the followings were excluded from the study: 1. Intracranial haemorrhage 2. Surgery or trauma within the preceding 3 months 3. Abnormal liver function 4. Haematology disorders 5. Renal insufficiency (serum creatinine greater than 1.5 mg/dL) 6. Malignancy 7. Febrile disorders 8. Acute or chronic inflammatory disease at study entry 9. Liver cirrhosis 10. Atrial fibrillation 11. Congestive heart failure 12. Contraindications for magnetic resonance imaging (MRI) examination 13. No evidence of acute IS by MRI study 14. Myeloproliferative disorder 15. Antibodies or being allergic to EPO 16. Pregnancy 17. Haemoglobin level greater than 15.0 g/dL |
| Date of first enrolment | 01/10/2008 |
| Date of final enrolment | 01/03/2010 |
Locations
Countries of recruitment
- Taiwan
Study participating centre
123, Ta Pei Road
Kaohsiung Hsien
83301
Taiwan
83301
Taiwan
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 25/02/2015 | Yes | No | |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
14/01/2016: Publication reference added.
